TYROSINEMIA-II

 

TYROSINEMIA- 2

 

DEFINITION:

A disorder of tyrosine metabolism characterized by the build-up of tyrosine resulting in oculocutaneous lesions.

EPIDEMIOLOGY:

  • incidence: rare
  • age of onset:
    • first few months of life
  • risk factors:
    • familial - autosomal recessive
      • chrom.#: 16q22.1-q22.3
      • gene: tyrosine aminotransferase (TAT)

PATHOGENESIS:

1. Background

  • tyrosine aminotransferase (TAT):
    • rate limiting enzyme in tyrosine metabolism
    • found predominantly in the liver
    • transaminates tyrosine to p-OH-phenylpyruvic acid
  • disorder first described in 1938 and connection to tyrosine metabolism established in 1973

2. Genetic Defect

  • mutation in the gene coding for TAT -> accumulation of tyrosine
  • tyrosine levels in the plasma and tissues excede saturation
  • formation of long, slender, birefringent tyrosine crystals intracellularly -> accumulate in the eyes and skin -> stimulate an inflammatory response with PMN leukocytes, edema, neovascularization -> ocular and skin lesions
  • liver and renal functions are not affected
  • in TYROSINEMIA-II, the damage is not done by the build-up of tyrosine but by its metabolites while in TYROSINEMIA-III, the damage is done by tyrosine directly

CLINICAL FEATURES:

1. Ocular Manifestations

  • appear during the first few months of life:
    • lacrimation, photophobia, redness
    • corneal herpetiform erosins/ulcers
    • dendritic ulcers
    • corneal and conjunctival plaques
    • neovascularization
  • long-term complications:
    • cataracts, corneal scarring, exodeviation, glaucoma, nystagmus, opacifications, visual impairment

2. Cutaneous Manifestations

  • begin with or after the ocular manifestations
  • skin lesions:
    • begin as blisters or erosions -> crust -> hyperkeratotic
    • painful, nonpruritic, sometimes hyperhidrosis
    • limited to palms and soles (particularly tips of digits, thenar and hypothenar eminences)
    • appear linear or subungual

3. Neurological Manifestations

  • normal intelligence -> moderate mental retardation
  • self-mutilating behaviour
  • disturbances of fine coordination

INVESTIGATIONS:

1. Serum

  • tyrosinemia is diagnostic (levels higher than in TYROSINEMIA-II)

2. Urine

  • tyrosinuria and tyrosyluria
  • elevated tyrosine metabolites
  • no other amino acids elevated

3. Liver Biopsy

  • decreased TAT activity

MANAGEMENT:

1. Diet

  • low tyrosine and phenylalanine diet
  • can correct tyrosinemia
  • results in a draumatic and rapid healing of eye and skin lesions and can prevent mental retardation
  •  

 

Pediatric Database - TYROSINEMIA-II

Pediatric Organization - Pedbase [at] Gmail.com